The Hovione Group revealed its yearly figures for 2005, which
revealed that sales grew by 8 per cent. The company's performance
is in contrast to the pharma fine chemicals sector, which between
2002 and 2004 had an average 14...
Cambrex has recorded a gain in the second quarter of this year,
with growth in its Bioproducts and Human Health segments. The
performances overshadow the company's troublesome BioPharma
division, indicative of a market for outsourced...
Swiss chemicals firm and contract manufacturer Lonza fulfilled its
promise of stronger financial results in the first half of 2005,
with profits coming in at the lower end of the forecast range, but
still on target, reports Phil Taylor.
US drug major Bristol-Myers Squibb has turned to Celltrion, a
company based in South Korea, for the manufacture of biologic
drugs, in another example of companies 'offshoring' production to
Asia, reports Phil Taylor.
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Switzerland's Siegfried Group, a specialist in active
pharmaceutical ingredients (APIs), dosage forms and
biopharmaceuticals, has boosted its position in the production of
controlled substances with the acquisition of US-based...
Italy's fine chemicals industry organisation, Afaquim, is
organising a conference in September aimed at coordinating the
efforts of European active pharmaceutical ingredient (API)
suppliers in the face of increasing competition...